Kuros Biosciences (CHF) traded down 0.90% on Monday, closing at CHF 17.57. Intraday, the share briefly touched CHF 17.20, marking the lowest price since April 2025 – an 18‑month trough. The decline follows a Friday session in which the stock fell 1.88% to CHF 17.73 before ending the day at CHF 17.54, already near the same low.
The recent slide extends a multi‑week downtrend that has taken the share from a mid‑range high of CHF 24.50 to its current level, a drop of roughly 28.3%. The steep price fall is attributed to a high price‑to‑earnings multiple of 101.7×, which analysts say leaves little margin for error, and to continued short‑selling pressure that dampens broader investor sentiment.
Analyst coverage remains uniformly bullish. The average target price compiled by the news agency AWP is CHF 33.76, implying more than 90% upside over the next twelve months. All five analysts surveyed rate Kuros as a "Buy" – none assign "Hold" or "Sell" recommendations. Berenberg’s Christian Ehmann projects a target of CHF 32 and recommends buying, while UBS analyst Tanya Hansalik sets a CHF 33 target and also advises a purchase.
Kuros reported its first‑half‑2026 results in mid‑August. Revenue rose 45% year‑on‑year to US$92.4 million. After a net loss of US$2 million in the same period a year earlier, the company posted a net profit of US$4.4 million. EBITDA margin improved to 13.6% from 12.3% in the prior year.
Management reaffirmed its growth outlook, targeting 35% revenue expansion and an EBITDA margin of about 14% for the full 2026 fiscal year. For 2028, the company projects revenue of US$300‑330 million and an EBITDA margin of at least 20%.
The combination of a steep price decline, elevated valuation multiples, and strong short‑seller activity has kept the stock under pressure despite the positive earnings trajectory and optimistic analyst forecasts.
